Results 141 to 150 of about 14,668 (165)

AL Cardiac Amyloidosis in Resource-Limited Settings: Diagnostic Challenges and Therapeutic Gaps. [PDF]

open access: yesJACC Case Rep
Torres-Valencia J   +6 more
europepmc   +1 more source

Efficacy and Safety of Durvalumab Combined With Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

open access: yesCancers, 2021
Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also has
Athanasios Dimopoulos   +2 more
exaly   +4 more sources

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [PDF]

open access: yesNew England Journal of Medicine, 2021
Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells.
Jin Lu   +2 more
exaly   +5 more sources

Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma [PDF]

open access: yesNew England Journal of Medicine, 2018
BACKGROUND The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.
Kenshi Suzuki   +2 more
exaly   +5 more sources

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

open access: yesNew England Journal of Medicine, 2016
BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma.
Albert Oriol   +2 more
exaly   +4 more sources

Monitoring Multiple Myeloma Patients Treated With Daratumumab: Teasing Out Monoclonal Antibody Interference [PDF]

open access: yesClinical Chemistry and Laboratory Medicine, 2016
BACKGROUND: Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclonal antibodies have the potential to be identified by serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE).
Jordan Schecter   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy